Picture of wind turbine against blue sky

Open Access research with a real impact...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

The Energy Systems Research Unit (ESRU) within Strathclyde's Department of Mechanical and Aerospace Engineering is producing Open Access research that can help society deploy and optimise renewable energy systems, such as wind turbine technology.

Explore wind turbine research in Strathprints

Explore all of Strathclyde's Open Access research content

Effect of combination therapy on immunological progression of Human Immunodeficiency virus at a population level

Parpia, T. and Raab, G.M. and Goldberg, D.J. and Allardice, G.M. and McMenamin, J. and Whitelaw, J. and McSharry, C. and Potts, R. and Herriot, R. (2001) Effect of combination therapy on immunological progression of Human Immunodeficiency virus at a population level. American Journal of Epidemiology, 153 (9). pp. 898-902. ISSN 0002-9262

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

There is accumulating evidence from clinical trials and cohort studies that highly active antiretroviral combination therapy is effective at halting immunologic and clinical progression of human immunodeficiency virus (HIV). Its impact at a population level is less well known because the regimes may be difficult to tolerate and compliance poorer. The authors make use of population data for almost all of the HIV-infected people in Scotland in 1997 who were under clinical care and monitor their response to therapy during the first year when these effective treatments became widely available. More than two thirds of the HIV-positive patients were on some form of antiretroviral therapy during the year. The authors show that all treated groups, even those who were on changing regimes, showed net improvement in immunologic status during the year. For the group of patients on triple or quadruple therapy, there was an average increase of more than 100 CD4 cells/mm3 over the year, with other treatment groups showing more modest, but significant, increases.